New preclinical data from the Garvan Institute of Medical Research has shown that Patrys’ deoxymab antibody PAT-DX1 is able to slow tumour growth and increase survival in an animal model of pancreatic cancer.
The study, conducted by Associate Professor Marina Pajic, showed that twice weekly treatment with PAT-DX1 for 4 weeks was able to significantly reduce the growth of pancreatic tumours by 26% and increase median survival by 47%.
Pancreatic cancer remains one of the most challenging cancers to treat, with fewer than 25% of patients surviving their first year after diagnosis. Patrys’ deoxymabs have natural tumour targeting qualities, allowing them to bind to DNA and disrupt the tumour’s intracellular DNA Damage Repair systems. This makes them a promising candidate for a range of hard to treat cancers.
Patrys CEO and MD, Dr James Campbell said:
The demonstration that PAT-DX1 is able to inhibit growth and improve survival in an animal model of pancreatic cancer validates the approach we are taking with our deoxymab antibody platform. We recently reported on the ability of PAT-DX1 to cross the blood brain barrier and treat both primary and secondary brain cancers. This new data from Garvan reinforces that Patrys’s deoxymabs may also have clinical utility for the treatment of non-brain cancers as well.